PT Diagnos Laboratorium Utama Tbk (DGNS.JK)
IDR 210.0
(0.0%)
IDR 210.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.53 Billion IDR | -111.67% |
| 2022 | 31.38 Billion IDR | -65.23% |
| 2021 | 90.84 Billion IDR | 25.35% |
| 2020 | 70.81 Billion IDR | 358.45% |
| 2019 | 14.89 Billion IDR | 20.32% |
| 2018 | 12.63 Billion IDR | 545.75% |
| 2017 | 1.84 Billion IDR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 4.31 Billion IDR | 267.14% |
| 2024 Q2 | 3.56 Billion IDR | -8.64% |
| 2023 Q2 | -925.7 Million IDR | -1230.32% |
| 2023 Q3 | 752.2 Million IDR | 181.26% |
| 2023 Q1 | 81.89 Million IDR | -98.24% |
| 2023 FY | - IDR | -98.06% |
| 2023 Q4 | 691.54 Million IDR | -8.06% |
| 2022 Q4 | 4.64 Billion IDR | -28.59% |
| 2022 Q3 | 6.5 Billion IDR | 17.06% |
| 2022 Q2 | 5.55 Billion IDR | -61.18% |
| 2022 FY | - IDR | -65.23% |
| 2022 Q1 | 14.31 Billion IDR | 287344.31% |
| 2021 Q1 | 28.99 Billion IDR | -7.39% |
| 2021 FY | - IDR | 25.35% |
| 2021 Q4 | -4.98 Million IDR | -100.02% |
| 2021 Q2 | 32.29 Billion IDR | 11.41% |
| 2021 Q3 | 27.55 Billion IDR | -14.69% |
| 2020 Q4 | 31.3 Billion IDR | 19.71% |
| 2020 Q1 | 2.72 Billion IDR | -35.49% |
| 2020 FY | - IDR | 358.45% |
| 2020 Q2 | 10.06 Billion IDR | 269.03% |
| 2020 Q3 | 26.15 Billion IDR | 159.72% |
| 2019 Q3 | 4.22 Billion IDR | 44.66% |
| 2019 Q2 | 2.92 Billion IDR | -0.0% |
| 2019 FY | - IDR | 20.32% |
| 2019 Q1 | 2.92 Billion IDR | 0.0% |
| 2019 Q4 | 4.22 Billion IDR | 0.0% |
| 2018 FY | - IDR | 545.75% |
| 2017 FY | - IDR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| PT Prodia Widyahusada Tbk | 527.17 Billion IDR | 99.709% |